

Brockton  
Video Media

## **Video Media**

On September 7, 2006 Dr. Assaad Sayah presented information on the IMMEDIATE Trial, to 52 attendees at a luncheon hosted by the Brockton Council on Aging. The presentation was televised on Brockton Community Access Cable and aired nine times during day and evening hours between September 25, 2006 and October 1, 2006. A printout of the Power Point presentation follows.

Immediate Myocardial Metabolic Enhancement  
**IMMEDIATE TRIAL**  
During Initial Assessment and Treatment in Emergency care

DATE: September 7, 2006

LOCATION: Brockton Council on Aging  
10 Father Kenney Way

PRESENTOR: Dr. Assaad Sayah,  
Medical Director of Brockton  
Emergency Medical Response

Immediate Myocardial Metabolic Enhancement  
**IMMEDIATE TRIAL**  
During Initial Assessment and Treatment in Emergency care

### *What is the IMMEDIATE Trial?*

A nationwide study that is testing whether giving an intravenous solution of Glucose, Insulin, and Potassium, (GIK) is helpful to patients at the first signs of a heart attack.

## *Research Team and Sponsors*

### Research team:

- Brockton Emergency Medical Service (EMS)  
Operated by American Medical Response (AMR)
- Brockton Hospital
- Caritas Good Samaritan Hospital
- Center for Cardiovascular Health Services  
Research at Tufts-New England Medical Center

### Sponsored by:

- National Institutes of Health
  - National Heart Lung and Blood Institute

## *Why are we here?*

- ✓ Enrollment in the Trial is being done during an emergency situation.
- ✓ Not feasible to obtain informed consent prior to starting the study drug.
- ✓ Patients may not be physically or emotionally able to understand the study and make an informed decision to participate.
- ✓ To test GIK at the earliest possible time, it must be initiated as soon as possible after the onset of symptoms.
- ✓ Provide the details of the study and hear your questions and comments

## *Background*

In the United States each year, there are...

- ❖ 1.2 million heart attacks
- ❖ 1.8 million unstable angina episodes
- ❖ 500,000 deaths: 300,000 out of hospital  
200,000 in hospital

Early recognition and treatment of heart attack symptoms is very important

© 2005, 2006

## *Heart Attack Warning Signs*

- ❖ Chest Discomfort  
(pressure, squeezing, fullness or pain)
- ❖ Discomfort in other areas of upper body  
(both arms, back, neck, jaw, stomach)
- ❖ Shortness of Breath  
(with or without chest pain)
- ❖ Other signs  
(cold sweat, nausea, light-headedness)

© 2005, 2006

## *Why are we doing this study?*

To test if GIK can prevent threatening heart attacks from occurring, and for heart attacks already underway, can decrease serious complications and death.



Copyright © 2011


## *What is the study drug?*

### GIK

- Glucose: Sugar, provides fuel to the heart when there is a reduced blood supply.
- Insulin: Hormone, it moves the glucose into the cells.
- Potassium: Salt, found in many foods and stored in the blood.

### Placebo

- Standard IV solution of sugar and water.



Copyright © 2011

## *Randomization*

- ❖ 50% Placebo
- ❖ 50% GIK
- ❖ Double-blind




© 2004, 2005

## *Who will be in the study?*

Potential participants must meet all of the following conditions:

- ✓ 30 years of age or older
- ✓ Heart attack symptoms
- ✓ EKG that indicates a heart attack
- ✓ Paramedic believes the patient is very likely to be having a heart attack



Note: Patients with diabetes may be enrolled in the Trial. Patient's glucose levels will be monitored.

© 2004, 2005

### *Who will not be in the study?*


- ∅ Less than 30 years of age
- ∅ Unconscious or unable to communicate
- ∅ Unable or unwilling to comply with study
- ∅ Undergoing dialysis for kidney disease
- ∅ Lungs congested with fluid
- ∅ Unstable medical condition, such as low blood pressure
- ∅ A prisoner

12/10/10/10


### *How will a patient be enrolled?*

#### **Ambulance**

- ❖ Patient meets study inclusion criteria
- ❖ Patients will not be provided with full informed consent prior to receiving the study drug.
- ❖ Paramedics will read an information card to the patient about the study.
- ❖ Patient may tell the paramedic that he/she ***does not want*** to participate in the study.



Standard of care continues



GIK or Placebo is started  
Standard of care continues

12/10/10/10

## *If enrolled, what happens?*

### **Hospital**

- ❖ Emergency department (ED) doctors will confirm diagnosis.
- ❖ Full informed consent will be obtained.
- ❖ GIK or Placebo will continue for 12 hours
- ❖ All other healthcare care will remain the same.
- ❖ Research staff will contact patient up to 3 times over the next year (30 days, 6 months and 1 year after hospital discharge).

## *What are the potential benefits of GIK?*

- ❖ Increase survival
- ❖ Decrease or slow the damage to the heart
- ❖ Allow other treatments a better chance of working
- ❖ Reduce the chance of congestive heart failure

### *What are the risks?*

- ❖ Redness, soreness or inflammation at the IV site.
- ❖ Potassium level changes (high or low) causing irregular heartbeat or dizziness.
- ❖ Blood sugar level changes (high or low) causing weakness, dizziness or thirstiness.
- ❖ Increased fluid in lungs
- ❖ Unknown or unanticipated risks

### *Where is the study being done?*


Multi-center (nationwide)

- ❖ Massachusetts Region (Concord and Brockton)
- ❖ Wisconsin (Milwaukee)
- ❖ Texas (Dallas)



## *Study Duration and Timeline Plans for Enrollment*

- ❖ Starts Fall 2006
- ❖ 2 year duration
- ❖ 24 hours a day / 7 days a week
- ❖ 15,450 patients to be enrolled nationwide



Page 1 of 4

## *Study Protocol*

- ❖ Financial Benefits: None
- ❖ Costs: None
- ❖ Alternative Procedures: None
- ❖ Confidentiality
  - ❖ Information will remain confidential
  - ❖ Access to Medical Records
    - **Research Staff**
    - **Food and Drug Administration (FDA) and the National Institutes of Health (NIH)**
    - **Study Coordinating Center (Tufts-NEMC)**
    - **Hospital Institutional Review Board (IRB)**

Page 2 of 4

## *Summary*

- ❖ You are having symptoms of a heart attack.
- ❖ You call 9-1-1 and Brockton EMS comes to care for you.
- ❖ Paramedic reads an information card about the study. You may decline participation.
- ❖ Study drug is started in the ambulance and continued for up to 12 hours.
- ❖ Paramedic notifies the emergency room doctor that you are enrolled in the study.
- ❖ You (or family member) receive a detailed description of the study (informed consent form) after arrival at the hospital and you are asked to decide if you would like to continue with the study.
- ❖ Standard of care continues.

## *Community Consultation*

- ❖ Feedback/Concerns
- ❖ Questions or Comments
- ❖ Discussion





*For more information please contact:*

Assaad Sayah, MD  
Director of Brockton American Medical Response  
(AMR)  
Brockton, MA  
Office: (617) 546-1708

Good Samaritan Hospital IRB (508) 427-2328

*Thank you!*